Blood metabolome predicts gut microbiome α-diversity in humans.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
10 2019
Historique:
received: 08 01 2019
accepted: 23 07 2019
pubmed: 4 9 2019
medline: 7 11 2019
entrez: 4 9 2019
Statut: ppublish

Résumé

Depleted gut microbiome α-diversity is associated with several human diseases, but the extent to which this is reflected in the host molecular phenotype is poorly understood. We attempted to predict gut microbiome α-diversity from ~1,000 blood analytes (laboratory tests, proteomics and metabolomics) in a cohort enrolled in a consumer wellness program (N = 399). Although 77 standard clinical laboratory tests and 263 plasma proteins could not accurately predict gut α-diversity, we found that 45% of the variance in α-diversity was explained by a subset of 40 plasma metabolites (13 of the 40 of microbial origin). The prediction capacity of these 40 metabolites was confirmed in a separate validation cohort (N = 540) and across disease states, showing that our findings are robust. Several of the metabolite biomarkers that are reported here are linked with cardiovascular disease, diabetes and kidney function. Associations between host metabolites and gut microbiome α-diversity were modified in those with extreme obesity (body mass index ≥ 35), suggesting metabolic perturbation. The ability of the blood metabolome to predict gut microbiome α-diversity could pave the way to the development of clinical tests for monitoring gut microbial health.

Identifiants

pubmed: 31477923
doi: 10.1038/s41587-019-0233-9
pii: 10.1038/s41587-019-0233-9
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1217-1228

Auteurs

Tomasz Wilmanski (T)

Institute for Systems Biology, Seattle, WA, USA.

Noa Rappaport (N)

Institute for Systems Biology, Seattle, WA, USA.

John C Earls (JC)

Institute for Systems Biology, Seattle, WA, USA.

Andrew T Magis (AT)

Arivale, Seattle, WA, USA.
Institute for Systems Biology, Seattle, WA, USA.

Ohad Manor (O)

Arivale, Seattle, WA, USA.

Jennifer Lovejoy (J)

Institute for Systems Biology, Seattle, WA, USA.
Arivale, Seattle, WA, USA.

Gilbert S Omenn (GS)

Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.

Leroy Hood (L)

Institute for Systems Biology, Seattle, WA, USA. lhood@systemsbiology.org.

Sean M Gibbons (SM)

Institute for Systems Biology, Seattle, WA, USA. sgibbons@systemsbiology.org.
eScience Institute, University of Washington, Seattle, WA, USA. sgibbons@systemsbiology.org.

Nathan D Price (ND)

Institute for Systems Biology, Seattle, WA, USA. nathan.price@systemsbiology.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH